Notice Pursuant to the National Cooperative Research and Production Act of 1993-Medical CBRN Defense Consortium, 53401 [2020-18979]
Download as PDF
<![CDATA[
Federal Register / Vol. 85, No. 168 / Friday, August 28, 2020 / Notices
Ware Corp., Palo Alto, CA; Bowhead
Health, Inc., Kanato, CANADA; and
Jason Mesut (individual member),
Twickenham, UNITED KINGDOM have
been added as parties to this venture.
Also, Cambridge Semantics
Incorporated, Boston, MA; WuXi
AppTec, Shanghai, PEOPLE’S
REPUBLIC OF CHINA; Phenomic AI
Inc., Toronto, CANADA; and Avantor
Performance Materials (formerly VWR
International), Darmstadt, GERMANY
have withdrawn as parties to this
venture. No other changes have been
made in either the membership or
planned activity of the group research
project. Membership in this group
research project remains open and
Pistoia Alliance, Inc. intends to file
additional written notifications
disclosing all changes in membership.
On May 28, 2009, Pistoia Alliance,
Inc. filed its original notification
pursuant to Section 6(a) of the Act. The
Department of Justice published a notice
in the Federal Register pursuant to
Section 6(b) of the Act on July 15, 2009
(74 FR 34364).
The last notification was filed with
the Department on April 24, 2020. A
notice was published in the Federal
Register pursuant to Section 6(b) of the
Act on May 19, 2020 (85 FR 29975).
Suzanne Morris,
Chief, Premerger and Division Statistics,
Antitrust Division.
[FR Doc. 2020–18973 Filed 8–27–20; 8:45 am]
BILLING CODE 4410–11–P
DEPARTMENT OF JUSTICE
Antitrust Division
Notice Pursuant to the National
Cooperative Research and Production
Act of 1993—Medical CBRN Defense
Consortium
Notice is hereby given that, on July
30, 2020, pursuant to Section 6(a) of the
National Cooperative Research and
Production Act of 1993, 15 U.S.C. 4301
et seq. (‘‘the Act’’), Medical CBRN
Defense Consortium (‘‘MCDC’’) has filed
written notifications simultaneously
with the Attorney General and the
Federal Trade Commission disclosing
changes in its membership. The
notifications were filed for the purpose
of extending the Act’s provisions
limiting the recovery of antitrust
plaintiffs to actual damages under
specified circumstances. Specifically,
Abiogenix, Inc.; Rochester, MI; ANP
Technologies, Inc.; Newark, DE;
Arcturus UAV, Inc.; Petaluma, CA;
AstraZeneca Pharmaceuticals, LP;
Gaithersburg, MD; Blade Therapeutics,
VerDate Sep<11>2014
17:16 Aug 27, 2020
Jkt 250001
Inc.; South San Francisco, CA;
Celularity, Inc.; New York, NY;
Commonwealth Trading Partners, Inc.;
Alexandria, VA; Cytonus Therapeutics,
Inc.; Columbus, OH; D. Wheatley
Enterprises, Inc.; Belcamp, MD;
ElectroNucleics, Inc.; Placentia, CA;
Fast-Track Drugs & Biologics, LLC;
Poolesville, MD; Fry Laboratories, LLC;
Scottsdale, AZ; Full Effect Biotech, Inc.;
Kansas City, KS; GAP Solutions, Inc.;
Herndon, VA; iBio CDMO LLC; Bryan,
TX; iBio, Inc.; New York, NY;
Massachusetts Eye and Ear Infirmary;
Boston, MA; MicroHealth LLC; Vienna,
VA; Novavax, Inc.; Gaithersburg, MD;
Pfizer, Inc.; New York, NY; Planet
Biotechnology, Inc.; Hayward, CA;
Primmune Therapeutics, Inc.; San
Diego, CA; Quantum Leap Healthcare
Collaborative; San Francisco, CA;
QuickSilver Analytics, Inc.; Hampstead,
NC; Regeneron Pharmaceuticals, Inc.;
Tarrytown, NY; Resonant Sensors, Inc.;
Arlington, TX; Rubix Strategies LLC;
Lawrence, MA; Shift Labs, Inc.; Seattle,
WA; SiO2 Medical Products, Inc.;
Auburn, AL; Space Information
Laboratories; Santa Maria, CA; Teledyne
Brown Engineering, Inc.; Huntsville,
AL; TensorX Inc.; Vienna, VA; Tunnell
Consulting, Inc.; Bethesda, MD;
Ultimaxx Health, Inc.; Boca Raton, FL;
University of Delaware on behalf of
NIIMBL; Newark, DE; University of
Louisville; Louisville, KY; Vaxart, Inc.;
South San Francisco, CA; Zeteo
Biomedical LLC; Austin, TX have been
added as parties to this venture.
Also, Onyx Government Services;
Centreville, VA; Space Information
Laboratories; Santa Maria, CA, Valaria
Technical Consultants, LLC;
Westminister, MD have withdrawn from
this venture.
No other changes have been made in
either the membership or planned
activity of the group research project.
Membership in this group research
project remains open, and MCDC
intends to file additional written
notifications disclosing all changes in
membership.
On November 13, 2015, MCDC filed
its original notification pursuant to
Section 6(a) of the Act. The Department
of Justice published a notice in the
Federal Register pursuant to Section
6(b) of the Act on January 6, 2016 (81
FR 513).
The last notification was filed with
the Department on April 30, 2020. A
notice was published in the Federal
PO 00000
Frm 00085
Fmt 4703
Sfmt 9990
53401
Register pursuant to Section 6(b) of the
Act on May 19, 2020 (85 FR 29976).
Suzanne Morris,
Chief, Premerger and Division Statistics,
Antitrust Division.
[FR Doc. 2020–18979 Filed 8–27–20; 8:45 am]
BILLING CODE P
DEPARTMENT OF JUSTICE
Antitrust Division
Notice Pursuant to the National
Cooperative Research and Production
Act of 1993—UHD Alliance, Inc.
Notice is hereby given that, on July
28, 2020, pursuant to Section 6(a) of the
National Cooperative Research and
Production Act of 1993, 15 U.S.C. 4301
et seq. (‘‘the Act’’), UHD Alliance, Inc.
(‘‘UHD Alliance’’) filed written
notifications simultaneously with the
Attorney General and the Federal Trade
Commission disclosing changes in its
membership. The notifications were
filed for the purpose of extending the
Act’s provisions limiting the recovery of
antitrust plaintiffs to actual damages
under specified circumstances.
Specifically, Toshiba Visual Solutions
Corporation (formerly Toshiba Lifestyle
Products & Services Corporation),
Tokyo, JAPAN has withdrawn as a party
to this venture.
No other changes have been made in
either the membership or planned
activity of the group research project.
Membership in this group research
project remains open, and UHD Alliance
intends to file additional written
notifications disclosing all changes in
membership.
On June 17, 2015, UHD Alliance filed
its original notification pursuant to
Section 6(a) of the Act. The Department
of Justice published a notice in the
Federal Register pursuant to Section
6(b) of the Act on July 17, 2015 (80 FR
42537).
The last notification was filed with
the Department on May 12, 2020. A
notice was published in the Federal
Register pursuant to Section 6(b) of the
Act on May 27, 2020 (85 FR 31808).
Suzanne Morris,
Chief, Premerger and Division Statistics,
Antitrust Division.
[FR Doc. 2020–18963 Filed 8–27–20; 8:45 am]
BILLING CODE P
E:\FR\FM\28AUN1.SGM
28AUN1
]]>Agencies
[Federal Register Volume 85, Number 168 (Friday, August 28, 2020)]
[Notices]
[Page 53401]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-18979]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Antitrust Division
Notice Pursuant to the National Cooperative Research and
Production Act of 1993--Medical CBRN Defense Consortium
Notice is hereby given that, on July 30, 2020, pursuant to Section
6(a) of the National Cooperative Research and Production Act of 1993,
15 U.S.C. 4301 et seq. (``the Act''), Medical CBRN Defense Consortium
(``MCDC'') has filed written notifications simultaneously with the
Attorney General and the Federal Trade Commission disclosing changes in
its membership. The notifications were filed for the purpose of
extending the Act's provisions limiting the recovery of antitrust
plaintiffs to actual damages under specified circumstances.
Specifically, Abiogenix, Inc.; Rochester, MI; ANP Technologies, Inc.;
Newark, DE; Arcturus UAV, Inc.; Petaluma, CA; AstraZeneca
Pharmaceuticals, LP; Gaithersburg, MD; Blade Therapeutics, Inc.; South
San Francisco, CA; Celularity, Inc.; New York, NY; Commonwealth Trading
Partners, Inc.; Alexandria, VA; Cytonus Therapeutics, Inc.; Columbus,
OH; D. Wheatley Enterprises, Inc.; Belcamp, MD; ElectroNucleics, Inc.;
Placentia, CA; Fast-Track Drugs & Biologics, LLC; Poolesville, MD; Fry
Laboratories, LLC; Scottsdale, AZ; Full Effect Biotech, Inc.; Kansas
City, KS; GAP Solutions, Inc.; Herndon, VA; iBio CDMO LLC; Bryan, TX;
iBio, Inc.; New York, NY; Massachusetts Eye and Ear Infirmary; Boston,
MA; MicroHealth LLC; Vienna, VA; Novavax, Inc.; Gaithersburg, MD;
Pfizer, Inc.; New York, NY; Planet Biotechnology, Inc.; Hayward, CA;
Primmune Therapeutics, Inc.; San Diego, CA; Quantum Leap Healthcare
Collaborative; San Francisco, CA; QuickSilver Analytics, Inc.;
Hampstead, NC; Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; Resonant
Sensors, Inc.; Arlington, TX; Rubix Strategies LLC; Lawrence, MA; Shift
Labs, Inc.; Seattle, WA; SiO2 Medical Products, Inc.; Auburn, AL; Space
Information Laboratories; Santa Maria, CA; Teledyne Brown Engineering,
Inc.; Huntsville, AL; TensorX Inc.; Vienna, VA; Tunnell Consulting,
Inc.; Bethesda, MD; Ultimaxx Health, Inc.; Boca Raton, FL; University
of Delaware on behalf of NIIMBL; Newark, DE; University of Louisville;
Louisville, KY; Vaxart, Inc.; South San Francisco, CA; Zeteo Biomedical
LLC; Austin, TX have been added as parties to this venture.
Also, Onyx Government Services; Centreville, VA; Space Information
Laboratories; Santa Maria, CA, Valaria Technical Consultants, LLC;
Westminister, MD have withdrawn from this venture.
No other changes have been made in either the membership or planned
activity of the group research project. Membership in this group
research project remains open, and MCDC intends to file additional
written notifications disclosing all changes in membership.
On November 13, 2015, MCDC filed its original notification pursuant
to Section 6(a) of the Act. The Department of Justice published a
notice in the Federal Register pursuant to Section 6(b) of the Act on
January 6, 2016 (81 FR 513).
The last notification was filed with the Department on April 30,
2020. A notice was published in the Federal Register pursuant to
Section 6(b) of the Act on May 19, 2020 (85 FR 29976).
Suzanne Morris,
Chief, Premerger and Division Statistics, Antitrust Division.
[FR Doc. 2020-18979 Filed 8-27-20; 8:45 am]
BILLING CODE P
